We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood-Based Diagnostic Technology Accurately Detects Prenatal Exposure Syndromes and Birth Disorders

By LabMedica International staff writers
Posted on 01 Aug 2024

Researchers are employing sophisticated technology and artificial intelligence (AI) to improve the diagnosis of rare diseases and prenatal exposure-related birth abnormalities, as detailed in two studies featured in the American Journal of Human Genetics and Genetics in Medicine. More...

The technology, known as EpiSign, utilizes AI to analyze the epigenome — each individual's unique chemical code that overlays their DNA and regulates gene activity. Currently, EpiSign assists in diagnosing over 100 genetic conditions that have historically been challenging to detect.

The first study, conducted by the team at London Health Sciences Centre (LHSC, London, ON, Canada) that developed EpiSign, demonstrated its efficacy in identifying a group of birth disorders known as recurrent constellation of embryonic malformations (RCEMs). Despite being recognized for over seven decades, the specific causes and diagnostic markers for RCEMs have remained elusive, making it difficult to provide accurate diagnosis to affected families. EpiSign now offers a groundbreaking method to accurately detect RCEMs using just a blood test.

In the second study, the same research team applied EpiSign to identify a reliable biomarker for fetal valproate syndrome for the first time. This syndrome results from prenatal exposure to high levels of medications used in managing bipolar disorder, migraines, or epilepsy, leading to a range of neurodevelopmental issues in children, such as learning disabilities, communication and motor disorders, autism, and intellectual disabilities. This research is part of an ongoing effort by the EpiSign Discovery Research network, which is expanding to study and develop biomarkers for over 700 rare disorders. The team has highlighted the vast potential of this research, which could extend to diagnosing, prognosing, and treating a wide array of other conditions, including cancer.

“One in 20 people have a rare disease that could present at any point in their lives and can be caused by genes, environmental exposures, or their combined effects,” said Dr. Bekim Sadikovic, Lawson Scientist at LHSC, who developed the EpiSign technology. “We can help diagnose a growing number of genetic diseases and, now for the first time, we can look beyond the genome and accurately measure the impact of the environment.”

Related Links:
London Health Sciences Centre


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myocardial Infarction Test
Quidel Triage Cardio3 Panel
New
Amoebiasis Test
ELI.H.A Amoeba
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.